Testosterone enanthate 250 mg/mL

Basic Info

CAS Number	315-37-7
Active Ingredient	Testosterone, as the enanthate, cypionate, propionate or undecanoate ester, or as a testosterone blend
Dosage Form	Oil vial
Specification & Packaging	Strength: 250 mg/mL Pack: 1 × 10 mL vial Group: 02 Item No.: 28

Storage & Common Excipients

Storage Conditions	Tightly closed, protected from light, 15–25 °C. Blends typically use sesame/castor oil as vehicle and are likewise stored light-protected at room temperature; follow the label
Common Excipients	Typical oil formulation: castor/sesame/peanut oil, polysorbate 80, benzyl alcohol, benzyl benzoate, edetate disodium; confirm against COA

Product Introduction

Different esterified forms of testosterone, an androgen used to treat male hypogonadism. Testosterone blend combines several esters to approximate the physiological testosterone profile and reduce peak-trough fluctuation

Therapeutic Use

Primary or secondary male hypogonadism (delayed puberty, azoospermia/infertility, post-orchiectomy, post-chemotherapy), palliative treatment of breast cancer in women (with aromatase inhibitors), gender hormone therapy; indications follow the locally approved label

Mode of Action

Ester prodrug requiring esterase hydrolysis to testosterone; enanthate/cypionate are long-acting (about 2–3 weeks), propionate short-acting (several days), undecanoate very long-acting (months); some testosterone aromatises to oestradiol, so oestrogenic symptoms must be monitored

Administration & Monitoring

Deep intramuscular injection, individualised to the patient; monitor testosterone levels, PSA, full blood count (haemoglobin), lipids and liver function; periodically review prostate and cardiovascular risk during long-term therapy; monitor androgenic symptoms and lipids in women

Important Safety Information

Prescription medicine. Abuse causes dependence, testicular atrophy, reproductive suppression and psychiatric symptoms. Prohibited in athletes. Start at a lower dose in men over 65. Intermittent dosing or switching to daily oral/transdermal delivery reduces risks such as polycythaemia

Adverse Reactions

Injection-site erythema, pain, induration; acne, oily skin, alopecia; testicular atrophy, reduced sperm count and raised PSA in men; voice deepening, hirsutism, menstrual disturbance and acne in women; oedema, weight gain, hypertension; raised haemoglobin (polycythaemia), reduced HDL; hepatic toxicity with long-term use; insomnia and mood swings

Important Risks

Polycythaemia and polycythaemia-associated thrombotic events; increased cardiovascular event risk (heart failure, myocardial infarction); prostatic enlargement/cancer risk; aggravation of sleep apnoea; dyslipidaemia; dependence and withdrawal

Contraindications

Hypersensitivity; known or suspected prostate or breast cancer (except specialist-directed palliative use in breast cancer); pregnancy (especially transdermal gels); severe cardiac, hepatic or renal impairment; uncontrolled atherosclerotic heart disease, NYHA grade ≥ III heart failure, recent myocardial infarction or stroke; paediatric and adolescent use

Special Populations

Use with caution in children/adolescents (risk of premature epiphyseal closure); reduced starting dose in men over 65 and those with cardiovascular risk; contraindicated in pregnancy; not recommended in lactation

Usage Limitations

Prescription-only; discuss dosing intervals with the prescriber/pharmacist to reduce pharmacokinetic fluctuation; prohibited for competitive athletes; rotate injection sites; do not combine with other testosterone products

Anti-Doping Testing

Testosterone is on the WADA Prohibited List S1.1 (exogenous testosterone); urine testing uses GC-C-IRMS for the testosterone/androstenediol ratio (TS/AD), with the Athlete Biological Passport for longitudinal blood data; ester prodrugs are also detected

Product Quality Testing

Identification (HPLC/MS/FTIR), assay and content uniformity, related substances, clarity and particulate matter, fill volume, sterility and bacterial endotoxin, residual solvents, stability including in-use stability; COA and lot-to-lot consistency studies

Source & Verification Note

Ester CAS numbers (58-20-8 / 315-37-7 / 57-85-2 / 5949-44-0) confirmed; testosterone blend is a mixture with no single CAS.